DaVita initiated with an Overweight at Barclays. Barclays analyst Patrick Feeley started DaVita with an Overweight rating and $70 price target. The analyst likes the stock’s risk/reward heading into 2019 given the industry backdrop and what he expects to be “materially accretive” share repurchases next year following the sale of DaVita Medical Group.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.